Vaccinex, Inc. Announces Initiation of a Phase 1 Clinical Trial of VX15/2503 Antibody in Multiple Sclerosis Patients
1/7/2013 11:20:09 AM
More...
|
Vaccinex, Inc. Initiates Phase I Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors
1/4/2011 6:21:48 AM
More...
|
Vaccinex, Inc. Awarded Three Qualifying Therapeutic Discovery Project (QTDP) Grants Under the Patient Protection and Affordable Care Act of 2010 (PPACA)
11/2/2010 7:00:09 AM
More...
|
John E. Leonard, Ph.D. Joins the Scientific Advisory Board of Vaccinex, Inc.
3/5/2008 10:44:49 AM
More...
|
Vaccinex, Inc. Antibody Licensed to GlaxoSmithKline (GSK)
2/15/2008 1:47:41 PM
More...
|
Vaccinex, Inc. Announces Award of Key Patent in Europe for its Antibody Discovery Technology (ActivMab(R))
11/30/2007 9:51:24 AM
More...
|
Vaccinex, Inc. Announces Antibody Development and Commercialization Alliance in Multiple Sclerosis and Oncology
2/27/2007 11:13:55 AM
More...
|
OPi, SAS And Vaccinex, Inc. Announce License Of Fully Human Anti-IL6 Antibody
10/10/2006 10:56:40 AM
More...
|
Vaccinex, Inc. To Present At Antibody World Summit
5/23/2006 5:08:51 PM
More...
|
Vaccinex, Inc. Announces Antibody Collaboration With Schering AG (SHR)
2/10/2006 10:18:08 AM
More...
|
|